title: Early-stage returns?
abstract: Contrary to conventional thinking, there are compelling reasons for investors to consider early-stage life science ventures, especially in the context of a maturing biotech business 'ecosystem'.
authors.affiliation: Atlas Venture, 890 Winter Street, Suite 320, Waltham, Massachusetts 02451, USA. bbooth@atlasventure.com
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Booth
mesh_terms: D001709:Biotechnology / Q000191:economics* / Q000639:trends; D002202:Capital Financing / Q000191:economics* / Q000639:trends; D004345:Drug Industry / Q000191:economics* / Q000639:trends; D004465:Economic Competition; D007449:Investments / Q000191:economics* / Q000639:trends; D014481:United States